J Neuroimmunol. 2003 Jun;139(1-2):109-18
Koike F, Satoh J, Miyake S, Yamamoto T, Kawai M, Kikuchi S, Nomura K, Yokoyama K, Ota K, Kanda T, Fukazawa T, Yamamura T.
Department of Immunology, National Institute of Neuroscience, NCNP, 4-1-1 Ogawahigashi, Tokyo 187-8502, Kodaira, Japan
The molecular mechanisms for the interferon beta (IFNbeta) treatment of multiple sclerosis (MS) remain to be characterized.
Using cDNA microarray technology, we have compared the gene expression profile of T and non-T cells derived from relapsing-remitting MS before and after treatment with IFNbeta-1b.
IFNbeta treatment significantly altered expression of 21 genes out of 1263 at 3 and 6 months after treatment.
These genes included nine with IFN-responsive promoter elements.
Whereas there was no change in Th1 or Th2 marker genes, some of the changes were unexpected but coincided with the beneficial effect of IFNbeta in MS.